Genome-environment interactions and prospective technology assessment: evolution from pharmacogenomics to nutrigenomics and ecogenomics.

The relationships between food, nutrition science, and health outcomes have been mapped over the past century. Genomic variation among individuals and populations is a new factor that enriches and challenges our understanding of these complex relationships. Hence, the confluence of nutritional science and genomics-nutrigenomics--was the focus of the OMICS: A Journal of Integrative Biology in December 2008 (Part 1). The 2009 Special Issue (Part 2) concludes the analysis of nutrigenomics research and innovations. Together, these two issues expand the scope and depth of critical scholarship in nutrigenomics, in keeping with an integrated multidisciplinary analysis across the bioscience, omics technology, social, ethical, intellectual property and policy dimensions. Historically, the field of pharmacogenetics provided the first examples of specifically identifiable gene variants predisposing to unexpected responses to drugs since the 1950s. Brewer coined the term ecogenetics in 1971 to broaden the concept of gene-environment interactions from drugs and nutrition to include environmental agents in general. In the mid-1990s, introduction of high-throughput technologies led to the terms pharmacogenomics, nutrigenomics and ecogenomics to describe, respectively, the contribution of genomic variability to differential responses to drugs, food, and environment defined in the broadest sense. The distinctions, if any, between these newer fields (e.g., nutrigenomics) and their predecessors (e.g., nutrigenetics) remain to be delineated. For nutrigenomics, its reliance on genome-wide analyses may lead to detection of new biological mechanisms governing host response to food. Recognizing "genome-environment interactions" as the conceptual thread that connects and runs through pharmacogenomics, nutrigenomics, and ecogenomics may contribute toward anticipatory governance and prospective real-time analysis of these omics fields. Such real-time analysis of omics technologies and innovations is crucial, because it can influence and positively shape them as these approaches develop, and help avoid predictable pitfalls, and thus ensure their effective and ethical application in the laboratory, clinic, and society.

[1]  A. Blakeslee,et al.  Odor and taste blindness , 1931 .

[2]  L. H. Snyder INHERITED TASTE DEFICIENCY. , 1931, Science.

[3]  A. L. Fox The Relationship between Chemical Constitution and Taste. , 1932, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Motulsky Drug reactions enzymes, and biochemical genetics. , 1957, Journal of the American Medical Association.

[5]  F. Vogel Moderne Probleme der Humangenetik , 1959 .

[6]  W. Kalow Pharmacogenetics : heredity and the response to drugs , 1962 .

[7]  Brewer Gj Annotation: human ecology, an expanding role for the human geneticist. , 1971 .

[8]  F. Vogel,et al.  Human Genetic Variation in Response to Medical and Environmental Agents: Pharmacogenetics and Ecogenetics , 1979, Human Genetics, Supplement.

[9]  N. Holtzman,et al.  Genetic variation in nutritional requirements and susceptibility to disease: policy implications. , 1988, The American journal of clinical nutrition.

[10]  S. Harding Is Science Multicultural?: Postcolonialisms, Feminisms, and Epistemologies , 1998 .

[11]  F. Mayor The World Conference on Science , 1999, Science.

[12]  Ana María Cetto,et al.  World Conference on Science—'Science for the Twenty-first Century: A New Commitment' (Declaration on Science and the Use of Scientific Knowledge) , 2000 .

[13]  Ana Maria Ceto Science for the twenty-first century : a new commitment , 2000 .

[14]  A. Paterson,et al.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.

[15]  K. Carpenter History of Nutritional Science , 2001 .

[16]  A. Motulsky From pharmacogenetics and ecogenetics to pharmacogenomics. , 2002, Medicina nei secoli.

[17]  K. Carpenter,et al.  A short history of nutritional science: part 1 (1785-1885). , 2003, The Journal of nutrition.

[18]  Silvio Funtowicz,et al.  The Precautionary Principle: Implications for Risk Management Strategies , 2005, International journal of occupational medicine and environmental health.

[19]  V. Mooser,et al.  Nutrigenomics and nutrigenetics , 2004, Current opinion in lipidology.

[20]  L. Bertilsson,et al.  Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions , 2005 .

[21]  David L. Eaton,et al.  Gene-environment interactions fundamentals of ecogenetics , 2006 .

[22]  J. Wardle,et al.  Heritability of food preferences in young children , 2006, Physiology & Behavior.

[23]  E. Kolker,et al.  Protein identification and expression analysis using mass spectrometry. , 2006, Trends in microbiology.

[24]  D. Gurwitz,et al.  'Drug reactions, enzymes, and biochemical genetics': 50 years later. , 2007, Pharmacogenomics.

[25]  T. Spector,et al.  Dietary Patterns and Heritability of Food Choice in a UK Female Twin Cohort , 2007, Twin Research and Human Genetics.

[26]  Gail Javitt,et al.  ASHG Statement* on Direct-to-Consumer Genetic Testing in the United States , 2007, Obstetrics and gynecology.

[27]  B. Godard,et al.  Evidence-based management of nutrigenomics expectations and ELSIs. , 2007, Pharmacogenomics.

[28]  Z. Master,et al.  Selling Translational Research: Is Science a Value-Neutral Autonomous Enterprise? , 2008, The American journal of bioethics : AJOB.

[29]  G. Fattore,et al.  Avoiding adverse drug reactions by pharmacogenetic testing: A systematic review of the economic evidence in the case of TPMT and AZA-induced side effects , 2008, International Journal of Technology Assessment in Health Care.

[30]  B. Godard,et al.  Nutrigenomics and personalized diet: from molecule to intervention and nutri-ethics. , 2008, Omics : a journal of integrative biology.

[31]  David H. Guston,et al.  Innovation policy: not just a jumbo shrimp , 2008, Nature.

[32]  B. Tepper,et al.  Nutritional implications of genetic taste variation: the role of PROP sensitivity and other taste phenotypes. , 2008, Annual review of nutrition.

[33]  G. Ruaño,et al.  Pharmacogenetic testing in psychiatry: a review of features and clinical realities. , 2008, Clinics in laboratory medicine.

[34]  Ge Zhang,et al.  From Human Genetics and Genomics to Pharmacogenetics and Pharmacogenomics: Past Lessons, Future Directions , 2008 .

[35]  K. Morin Knowledge and attitudes of Canadian consumers and health care professionals regarding nutritional genomics. , 2009, Omics : a journal of integrative biology.

[36]  Ahmed El-Sohemy,et al.  Genetic variation in taste and its influence on food selection. , 2009, Omics : a journal of integrative biology.

[37]  J. Leon The future (or lack of future) of personalized prescription in psychiatry. , 2009 .

[38]  T. Caulfield Nutrigenomics patents and commercialization: old wine in a new bottle? , 2009, Omics : a journal of integrative biology.

[39]  Eugene Kolker,et al.  Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. , 2009, Omics : a journal of integrative biology.

[40]  David H. Guston,et al.  Scientists Not Immune to Partisanship , 2009, Science.

[41]  R. de la Torre,et al.  Mononuclear cell transcriptome response after sustained virgin olive oil consumption in humans: an exploratory nutrigenomics study. , 2009, Omics : a journal of integrative biology.

[42]  A. Llerena,et al.  Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. , 2009, Pharmacogenomics.

[43]  L. Svetkey,et al.  The STEDMAN project: biophysical, biochemical and metabolic effects of a behavioral weight loss intervention during weight loss, maintenance, and regain. , 2009, Omics : a journal of integrative biology.

[44]  D. Gurwitz,et al.  Pharmacogenetics in Europe: Barriers and Opportunities , 2009, Public Health Genomics.